ACE2 and COVID-19: Early in COVID-19, SARS-CoV-2 enters pulmonary epithelial cells via surface angiotensin-converting enzyme 2 (ACE2) receptors, resulting in viral pneumonia, followed by a systemic inflammatory phase [1,2,3].